BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer

Aims: Recently, BRAF mutation testing has been introduced as a marker in differentiating Lynch syndrome from sporadic colorectal cancers or in predicting colorectal cancers with worse prognosis. Individuals with hereditary predisposition to cancer development are at an increased risk of developing multiple primary cancers. The purpose of this study is to identify mutation in the BRAF gene in multiple primary cancers with colorectal cancer and stomach cancer. Methods: BRAF mutation was analysed in 45 patients with colorectal cancer and stomach cancer, synchronously or metachronously. Results: Mean age was 64.07 years (range: 47–83 years). For the colorectal cancer, tumors were located at the sigmoid colon in eight patients (17.8%) and at the rectum in 22 patients (48.9%). Twenty-three patients (51.1%) had synchronous cancer. Four patients (8.9%) had family members with cancer. BRAF mutation was identified in three patients (6.7%). All three of these patients had metachronous cancers. The colorectal cancers were located in the sigmoid colon (1 patient) and the rectum (2 patients). Conclusions: BRAF mutation rate was low in the multiple primary cancer with colorectal cancer and stomach cancer. With only BRAF gene study, it was not possible to identify any correlation with family history of colorectal cancer. Further study means considering other genes – MSI, MSH2, MLH1, MSH6.

[1]  T. Muto,et al.  Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer , 2003, International Journal of Clinical Oncology.

[2]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[3]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[4]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[5]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[6]  L. Balducci,et al.  Multiple Primary Malignancies , 2009 .

[7]  C. Dodaro,et al.  “Sporadic” Colorectal Tumors in Multiple Primary Malignancies , 2009 .

[8]  R. Luben,et al.  Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study , 2010, BMC Cancer.

[9]  Y. Liao,et al.  Gene Mutations in Epidermal Growth Factor Receptor Signaling Network and Their Association With Survival in Chinese Patients With Metastatic Colorectal Cancers , 2010, Anatomical record.

[10]  Marc S. Williams,et al.  Lynch syndrome screening implementation: business analysis by a healthcare system. , 2011, The American journal of managed care.

[11]  W. Fang,et al.  Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. , 2011, World journal of gastroenterology.

[12]  P. Watson,et al.  The Tumor Spectrum in the Lynch Syndrome , 2004, Familial Cancer.

[13]  Seung-Hyun Lee,et al.  Multiple primary cancers in extracolonic sites with colorectal cancer , 2009, International Journal of Colorectal Disease.

[14]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[15]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[16]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[17]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.

[18]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.